Hikma Pharmaceuticals PLC

HIK · LSE

Public Market Listing

HIKLSE

LSE primary exchange listing

Live quotes, historical charts, and market capitalization for Hikma Pharmaceuticals PLC are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Cenobamate(Xcopri)
Approved
Sodium channels + GABA-A receptorsSmall molecule
Epilepsy
Focal Onset Seizures
Approved
GABA-A receptorSmall molecule
Epilepsy
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (2)
Cenobamate · XcopriPhase 2Epilepsies, Partial
Est. primary completion 2027-01-31 · NCT06590896 · CT.gov ↗
What to watch
Cenobamate · XcopriPhase 3Epilepsy, Generalized
Est. primary completion 2027-01-31 · NCT06579573 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Cenobamate · XcopriPhase 3Partial Epilepsy
Est. primary completion 2028-03-30 · NCT07594158 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

31 January 2027FDA action dateCenobamatePDUFA date set for cenobamate oral suspension
US, FDA · Source ↗

Recent

4 November 2026Filing submittedCenobamateSK Biopharmaceuticals submits sNDA for cenobamate in PGTC seizures and pediatric focal-onset seizures
US, FDA · SK Biopharmaceuticals · Source ↗
15 June 2026Filing acceptedCenobamateFDA accepts NDA for cenobamate oral suspension
US, FDA · Source ↗
27 May 2025Approvalustekinumab-hmny (Starjemza)FDA approves STARJEMZA (ustekinumab-hmny), a Stelara biosimilar
US, FDA · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$1.7B$73M$236M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.3B$151M$217M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.1B$141M$188M—report ↗
2023-FY$2.9B$149M$205M—report ↗
2022-FY$2.5B$144M$270M—report ↗
2021-FY$2.6B$143M$426M—report ↗